Xenon reports Q2 net loss of $57.9M; cash $850.6M; Phase 3 epilepsy data H2 2025

Xenon Pharmaceuticals Inc.

2024-Q2 EPS reported -$1.36

Net loss for Q2 2024 was $57.9M, compared to $47.5M in Q2 2023.
Cash and marketable securities $850.6M as of June 30, 2024, down from $930.9M at Dec 31, 2023; cash runway into 2027.
Phase 3 X-TOLE2 top-line FOS data anticipated H2 2025; MDD Phase 3 study to start H2 2024.
R&D expenses $49.7M (Q2 2024) vs $44.0M (Q2 2023); G&A $19.4M vs $11.6M.
Pre-clinical Kv7 and Nav1.7 candidates advancing; multiple INDs expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.